Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22499924 | 0.78 | — | — | |
| SCHEMBL27930886 | 0.78 | THRB (0.44) | ALDH1A1TSHRTHRB | |
| SCHEMBL5675768 | 0.78 | ALDH1A1 (0.37) | ALDH1A1TSHR | |
| SCHEMBL17713691 | 0.77 | TSHR (0.45) | ALDH1A1TSHRTHRB | |
| SCHEMBL9395883 | 0.76 | ALDH1A1 (0.35) | ALDH1A1TSHR | |
| SCHEMBL21300581 | 0.75 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL7634437 | 0.74 | TSHR (0.42) | ALDH1A1TSHRTHRB | |
| SCHEMBL28763054 | 0.72 | ALDH1A1 (0.39) | ALDH1A1TSHRTHRB | |
| SCHEMBL261665 | 0.71 | ALDH1A1 (0.52) | ALDH1A1TSHRTHRB | |
| SCHEMBL10340727 | 0.70 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4395749-B1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2025-11-19 | — | — | EP | disclosed |
| EP-3996692-B1 | TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING AN ACTIVE AGENT-CONTAINING LAYER COMPRISING A SILICONE-CONTAINING POLYMER AND A SKIN CONTACT LAYER COMPRISING A SILICONE GEL ADHESIVE | LTS LOHMANN THERAPIE SYSTEME AG (DE) | 2025-06-11 | — | — | EP | disclosed |
| US-12214088-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2025-02-04 | — | — | US | disclosed |
| CN-111465392-B | Transdermal therapeutic system for transdermal administration of guanfacine comprising a silicone polymer | 罗曼治疗系统股份公司 | 2024-12-17 | — | — | CN | disclosed |
| US-12168074-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-12-17 | — | — | US | disclosed |
| US-20240374544-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-11-14 | — | — | US | disclosed |
| US-12121616-B2 | Transdermal therapeutic system for the transdermal administration of solifenacin | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-10-22 | — | — | US | disclosed |
| US-12048770-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2024-07-30 | — | — | US | disclosed |
| CN-112040936-B | Transdermal therapeutic system for transdermal administration of solifenacin | 罗曼治疗系统股份公司 | 2024-07-23 | — | — | CN | disclosed |
| EP-4395749-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | LTS Lohmann Therapie-Systeme AG (DE) | 2024-07-10 | — | — | EP | disclosed |
| US-20140128539-A1 | SILICONE-ACRYLIC COPOLYMER | Henkel US IP LLC (US) | 2014-05-08 | — | — | US | disclosed |
| EP-2421928-B1 | SILICONE ACRYLIC HYBRID POLYMER-BASED ADHESIVES | HENKEL CORP (US) | 2014-03-05 | — | — | EP | disclosed |
| US-8664329-B2 | Silicone-acrylic copolymer | Henkel US IP LLC (US) | 2014-03-04 | — | — | US | disclosed |
| US-8580891-B2 | Silicone acrylic hybrid polymer-based adhesives | Henkel US IP LLC (US) | 2013-11-12 | — | — | US | disclosed |
| EP-2561008-A2 | SILICONE-ACRYLIC COPOLYMER | Henkel Corporation (US) | 2013-02-27 | — | — | EP | disclosed |
| US-20130012653-A1 | Silicone-Acrylic Copolymer | HENKEL CORPORATION (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120095159-A1 | Silicone Acrylic Hybrid Polymer-Based Adhesives | HENKEL AG & CO. KGAA (DE) | 2012-04-19 | — | — | US | disclosed |
| EP-2421928-A2 | SILICONE ACRYLIC HYBRID POLYMER-BASED ADHESIVES | Henkel Corporation (US) | 2012-02-29 | — | — | EP | disclosed |
| WO-2011133408-A2 | SILICONE-ACRYLIC COPOLYMER | HENKEL CORPORATION (US) | 2011-10-27 | — | — | WO | disclosed |
| WO-2010124187-A2 | SILICONE ACRYLIC HYBRID POLYMER-BASED ADHESIVES | HENKEL CORPORATION (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12168074-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone polymer | PDE2A, PDE3A, PDE3B | ALDH1A1 3487/4885TSHR 1050/4885THRB 285/4885 |
| US-12214088-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising at least one additive | GUCY1A2, PDE2A, PDE3A | ALDH1A1 2210/4885TSHR 2021/4885THRB 704/4885 |
| US-12121616-B2 | Transdermal therapeutic system for the transdermal administration of solifenacin | TPSB2, NTSR2, NTSR1 | ALDH1A1 3319/4885TSHR 156/4885THRB 41/4885 |
| US-20240374544-A1 | TRANSDERMAL THERAPEUTIC SYSTEM FOR THE TRANSDERMAL ADMINISTRATION OF GUANFACINE COMPRISING GUANFACINE AND A MONO-CARBOXYLIC ACID | GUCY1A2, MTHFD1, FPGS | ALDH1A1 1277/4885TSHR 1898/4885THRB 1374/4885 |
| US-12048770-B2 | Transdermal therapeutic system for the transdermal administration of guanfacine comprising a silicone acrylic hybrid polymer | PDE2A, PDE3A, GUCY1A2 | ALDH1A1 2530/4885TSHR 1158/4885THRB 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.